EDAP TMS S.A., each representing One Ordinary Share (EDAP): Price and Financial Metrics
EDAP Price/Volume Stats
| Current price | $7.02 | 52-week high | $12.65 |
| Prev. close | $6.66 | 52-week low | $5.78 |
| Day low | $6.76 | Volume | 72,700 |
| Day high | $7.13 | Avg. volume | 65,690 |
| 50-day MA | $7.69 | Dividend yield | N/A |
| 200-day MA | $9.86 | Market Cap | 259.12M |
EDAP Stock Price Chart Interactive Chart >
EDAP POWR Grades
- Sentiment is the dimension where EDAP ranks best; there it ranks ahead of 67.46% of US stocks.
- EDAP's strongest trending metric is Growth; it's been moving down over the last 178 days.
- EDAP ranks lowest in Growth; there it ranks in the 3rd percentile.
EDAP Stock Summary
- With a one year PEG ratio of 1.04, EDAP TMS SA is expected to have a higher PEG ratio (a measure of how expensive a stock is relative to its expected earnings growth) than merely 12.92% of US stocks.
- With a year-over-year growth in debt of -16.76%, EDAP TMS SA's debt growth rate surpasses only 18.78% of about US stocks.
- In terms of twelve month growth in earnings before interest and taxes, EDAP TMS SA is reporting a growth rate of -2,367.12%; that's higher than only 0.63% of US stocks.
- Stocks with similar financial metrics, market capitalization, and price volatility to EDAP TMS SA are DGLY, WFRD, GENC, TGEN, and ASYS.
- EDAP's SEC filings can be seen here. And to visit EDAP TMS SA's official web site, go to www.edap-tms.com.
EDAP TMS S.A., each representing One Ordinary Share (EDAP) Company Bio
EDAP TMS S.A. develops, produces, markets, distributes, and maintains a portfolio of minimally invasive medical devices for the treatment of urological diseases worldwide. The company was founded in 1979 and is based in Vaulx-en-Velin, France.
Latest EDAP News From Around the Web
Below are the latest news stories about EDAP TMS SA that investors may wish to consider to help them evaluate EDAP as an investment opportunity.
EDAP to Present at Morgan Stanley Annual Global Healthcare Conference and the H.C. Wainwright Annual Global Investment ConferenceLYON, France, September 6, 2023 -- EDAP TMS SA (Nasdaq: EDAP) (“the Company”), the global leader in robotic energy-based therapies, today announced that Ryan Rhodes, Chief Executive Officer, is scheduled to deliver a presentation and host 1x1 investor meetings at the upcoming Morgan Stanley 21st Annual Global Healthcare Conference and the H.C. Wainwright 25th Annual Global Investment Conference, both being held September 11-13, 2023, in New York City. H.C. Wainwright presentation details: Date:T |
EDAP TMS S.A. (NASDAQ:EDAP) Q2 2023 Earnings Call TranscriptEDAP TMS S.A. (NASDAQ:EDAP) Q2 2023 Earnings Call Transcript August 24, 2023 EDAP TMS S.A. beats earnings expectations. Reported EPS is $0.13, expectations were $-0.03. Operator: Greetings, and welcome to the EDAP TMS Second Quarter 2023 Earnings Conference Call. [Operator Instructions] As a reminder, this conference is being recorded. I would now like to turn […] |
EDAP Announces Second Quarter 2023 Financial Results- Record second quarter and first half revenues of EUR 14.3 million (USD 15.5 million) and EUR 29.1 million (USD 31.5 million), respectively - - Total HIFU Q2 2023 year-over-year revenue growth of 63.6% - - Strong Q2 2023 year-over-year U.S. Focal One® HIFU procedure growth of 85% - - Received reimbursement approval in Switzerland for use of HIFU in the treatment of prostate cancer - - More than half of patients now enrolled in Phase 3 study evaluating Focal One HIFU in endometriosis - - Appoint |
EDAP TMS SA to Announce Second Quarter 2023 Financial Results on August 24, 2023- Company to host conference call and webcast on Thursday, August 24th at 8:30 am EDT - LYON, France, August 10, 2023 - EDAP TMS SA (Nasdaq: EDAP), the global leader in robotic energy-based therapies, today announced that it will release its financial results for the second quarter ended June 30th, 2023, before the markets open on Thursday, August 24th, 2023. An accompanying conference call and webcast will be hosted by Ryan Rhodes, Chief Executive Officer, François Dietsch, Chief Financial Offi |
EDAP Announces Reimbursement Approval in Switzerland for the Use of High-Intensity Focused Ultrasound (HIFU) in the Treatment of Prostate CancerLYON, France, July 26, 2023 -- EDAP TMS SA (Nasdaq: EDAP) (“the Company”), the global leader in robotic energy-based therapies, today announced that it has received reimbursement approval in Switzerland for the use of High-Intensity Focused Ultrasound (HIFU) in the treatment of prostate cancer. This reimbursement took effect on July 1, 2023. "Receipt of appropriate reimbursement from the Swiss healthcare authorities is another acknowledgment of the growing, worldwide acceptance of HIFU as an eff |
EDAP Price Returns
| 1-mo | -10.12% |
| 3-mo | N/A |
| 6-mo | -32.82% |
| 1-year | -14.91% |
| 3-year | 56.00% |
| 5-year | 136.76% |
| YTD | -34.15% |
| 2022 | 77.96% |
| 2021 | 15.86% |
| 2020 | 16.70% |
| 2019 | 139.46% |
| 2018 | -35.54% |
Continue Researching EDAP
Here are a few links from around the web to help you further your research on Edap Tms Sa's stock as an investment opportunity:Edap Tms Sa (EDAP) Stock Price | Nasdaq
Edap Tms Sa (EDAP) Stock Quote, History and News - Yahoo Finance
Edap Tms Sa (EDAP) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...